Isoprenaline (ISO) at high doses can cause severe stress to myocardium resulting in an infarct-like necrosis in rats. However, its effects at repeatedly low dose exposure on heart, kidney and aorta are still unclear. Hence, this study was aimed to investigate the effects of repeated administration of low dose ISO on the organs in rats by using Langendorff-perfused isolated hearts, ELISA kits, qPCR and histopathology techniques. Male Wistar rats (n=24) were randomly divided into three groups which were given 5 or 10 mg/kg/day of ISO (ISO 5 and ISO 10, respectively), or normal saline (control) subcutaneously for 14 days. Blood pressure was recorded at day-0, 7 and 14. Heart, aorta, kidneys, and blood were then collected. ISO at both doses significantly increased the heart weight and blood pressure (p<0.05), while the heart rate was significantly decreased (p<0.05). ISO also increased serum troponin and NT-pro-BNP, and decreased vascular relaxation dose-dependently. Group ISO 10 showed significantly increased cardiomyocyte area and cardiac collagen content, as well as reduced serum nitrite (p<0.05). However, ISO at both doses did not affect the cardiac mechanical function, renal oxidative stress, inflammation, as well as renal gene expressions of angiotensin-converting enzyme and angiotensin II type 1 receptor. In conclusion, repeated low dose of ISO significantly causes myocardial injury and reduces vascular function in rats. The findings imply that this rat model could be a suitable model of heart injury without the complication of renal injury.
7 January 2020 in Current Pharmaceutical Biotechnology
Background: 17βH-neriifolin, a cardiac glycoside compound had been successfully isolated from Cerbera odollam leaves based on the bioassay guided-isolation procedure. The aim of these studies were to determine the in vitro anti-cancer and binding effects of 17βH-neriifolin on Na+, K+-ATPase.Methods: The in vitro anti-cancer effects were evaluated using Sulphorhodamine B and Hoescht 33342 assays. The Na+, K+-ATPase assay was carried out using Malachite Green assay. In silico molecular docking studies and in vitro malachite green assay were used to predict the binding activities of 17βH-neriifolin on Na+, K+-ATPase and ouabain was also included as for comparison studies.Results: The compound was tested against breast (MCF-7, T47D), colorectal (HT-29), ovarian (A2780, SKOV-3) and skin (A375) cancer cell lines that gave IC50 values ranged from 0.022 ± 0.0015 to 0.030 ± 0.0018 μM. The mechanism of cell death of 17βH-neriifolin was further evaluated using Hoescht 33342 assay and it was found that the compound killed the cancer cells via apoptosis. 17βHneriifolin and ouabain both bound at α-subunit in Na+, K+-ATPase and their binding energy were - 8.16 ± 0.74 kcal/mol and -8.18 ± 0.48 kcal/mol respectively.Conclusion: The results had confirmed the anti-proliferative effects exerted by 17βH-neriifolin in the breast, colorectal, ovarian and skin cancer cell lines. 17βH-neriifolin had shown to cause apoptotic cell death in the respective cancer cell lines.17βH-neriifolin and ouabain both bound at α-subunit in Na+, K+-ATPase and their binding energy were -8.16 ± 0.74 kcal/mol and -8.18 ± 0.48 kcal/mol respectively. This is the first report to reveal that 17βH-neriifolin managed to bind to the pocket of α-subunit of Na+.K+-ATPase.